Cardiovascular – AudioMedica.com: Recent Episodes
None
The interview was filmed in preparation for an article in Oncology Times
@OncologyTimes
BOSTON, MA—The risks of death from organ damage caused by COVID-19 infection have been quantified for each of a number of cardiovascular and other co-morbidities in an …
Audio Journal of Cardiovascular Medicine
Reporting from: 2016 European Society of Cardiology, Rome
Competitive and Leisure Sports: Recommendations to Minimise Cardiovascular Risk
ROME—Exercise benefits most patients with cardiovascular disease who can take part in leisure sports safely if they wish, …
Sanjay Sharma ESC PODCAST
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a myocardial infarction was scrutinised in a debate at the 2013 annual congress of the European Society of Cardiology here. …
AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in type II diabetes but has failed to show a benefit in terms of cardiovascular outcomes. At the …
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a myocardial infarction was scrutinised in a debate at the 2013 annual congress of the European Society of Cardiology here. …
LOS ANGELES—Half of young adults who had multiple, elevated, blood pressure results on recent outpatient visits to the doctor, went home without a hypertension diagnosis. Research presented at the 2012 American Heart Association meeting showed, after four years of trips …
LOS ANGELES—Regardless of climate, there are more deaths from heart-related issues in winter-time than in the summer. Results from a 12-year US population based study with over 220,000 people were presented at the American Heart Association meeting in Los Angeles …
LOS ANGELES—Looking older than your chronological age is a risk factor for cardiovascular disease — at least among white Caucasians — according to a study of over ten thousand Danish people from the general population who were first assessed for …
LOS ANGELES—A more powerful back-up drug for patients intolerant to statins was announced at the American Heart Association 2012 Scientific Sessions. A monoclonal antibody called: AMG 145 against a protein found to regulate LDL receptor activity — the PCSK 9 …
LOS ANGELES—A recombinant form of the human hormone relaxin — active in pregnancy to optimise the mother’s cardiovascular capacity — may help patients hospitalised for acute heart failure, according to findings discussed at the American Heart Association’s 2012 Scientific Sessions …
LOS ANGELES—Direct infusions of human HDL — to speedily boost HDL levels —could be an answer to preventing re-infarction in patients who’ve just had a heart attack and are at high risk of having another, according to conclusions from a …
LOS ANGELES—Aspirin has a new role: in preventing recurrent thromboembolism among patients who are not candidates for anti-coagulation — according to conclusions from the ASPIRE study reported to the American Heart Association’s 2012 Scientific Sessions. Dr Timothy Brighton of the …
LOS ANGELES—The “polypill” — a multi-drug pill — combining diuretic, ACE inhibitor, beta-blocker, statin and aspirin — brings even more benefit when it’s targeted at patients who are at elevated coronary risk rather than being used as a general “insurance” …
LOS ANGELES—The optimal revascularisation strategy for patients with diabetes and multi-vessel coronary disease was confirmed to be coronary artery bypass grafting rather than PCI at the American Heart Association 2012 Scientific Sessions. Valentin Fuster from Mount Sinai Hospital in …
ORLANDO—Deepak Bhatt from the VA Boston Healthcare System and Brigham & Women’s Hospital, talks with Peter Goodwin about findings from the CHAMPION-PLATFORM study (using cangrelor in PCI) and the PLATO study (with ticagrelor in ACS)—testing reversible ADP antagonist agents …
A fundamental change in the way hypertension is measured, and studies to identify evidence-based blood pressure goals have been highlighted as top priorities by one of Sweden’s prominent hypertension specialists, Björn Dahlöf, during the European Meeting on Hypertension.
MILAN—New …
The illusive angiotensin AT2 receptor could become an important new target for therapy in the overall care of patients with hypertension. A leading researcher in cardiovascular medical science has found that by stimulating this receptor his group discovered remarkable regenerative …
Eight human genes have been recognised as modulating blood pressure by a team from London, UK, presenting findings at the European Society of Hypertension’s annual conference. The researchers hope that these will provide targets for new drugs to treat hypertension.…
Peter Nilsson explains to Peter Goodwin his clear recommendation that doctors should manage hyperglycaemia aggressively in patients with Type II diabetes following his discussions in Milan about the meta-analysis of five big studies recently published in The Lancet which confirms …
A leading scientist from Prague has announced results showing a forty per cent reduction in cardiovascular mortality overall and a sixty per cent fall in stroke deaths between 1985 and 2007 in the Czech Republic. Renata Cifkova explains to Peter …
Hermann Haller tells Peter Goodwin about the significant health risks—including for renal disease, myocardial infarction and stroke—which are going undetected across Europe because doctors are not testing their patients who have hypertension for microalbuminuria. He discusses the findings of a …
New York cardiologist Franz Messerli explains to Peter Goodwin why he doesn’t prescribe the popular diuretic hydrochlorothiazide as initial therapy for hypertension any more, as he announced in a “Late-Breaker” session at the European Meeting on Hypertension in Milan.
php if (ereg("iPhone",$_SERVER['HTTP_USER_AGENT'])) { $iphone = 1 ; } else { $iphone = 0; } ?
php if ($iphone) { ?
LISTEN…
Josep Redon tells Peter Goodwin about a J-shaped relationship between lowering blood pressure and mortality uncovered by the ONTARGET study in patients with diabetes.
php if (ereg("iPhone",$_SERVER['HTTP_USER_AGENT'])) { $iphone = 1 ; } else { $iphone = 0; } ?
php if ($iphone) { ?
LISTEN
php } else { ?
[audio:https://www.audiomedica.com/podcasting/cardio/090612JosepRedonAUDIOnewsLoRes.mp3] php } ?…
Henry Krum, Monash University, Melbourne
ACC 58th Annual Scientific Session, 28-31 March, 2009, Orlando—Peter Goodwin interviews Henry Krum, Director of the Monash Centre of Cardiovascular Research & Education in Therapeutics at Monash University in Melbourne, Australia about a catheter-delivered …
Germano Di Sciascio, Campus Bio-Medico University, Rome
ACC 58th Annual Scientific Session, 28-31 March, 2009, Orlando—Peter Goodwin hears from Germano Di Sciascio of the Campus Bio-Medico University of Rome latest data on mortality from the Atorvastatin for Reduction of …
Daniel Mark
Peter Goodwin interviews Daniel Mark and Robert Jones from Duke University, Durham, North Carolina about the international STICH Trial with 1 000 patients which randomised patients with severe heart failure to receive coronary artery by-pass grafting alone or …
Salim Yusuf
Salim Yusuf, McMaster University, Hamilton
Peter Goodwin interviews Salim Yusuf, McMaster University, Hamilton.
php if (ereg("iPhone",$_SERVER['HTTP_USER_AGENT'])) { $iphone = 1 ; } else { $iphone = 0; } ?
php if ($iphone) { ?
LISTEN
php } else { ?
[audio:https://www.audiomedica.com/podcasting/cardio/090331SalimYusufINDIANpolypill.mp3] php } ?…
George Dangas
George Dangas, Columbia University, New York
Peter Goodwin interviews George Dangas, Columbia University, New York.
php if (ereg("iPhone",$_SERVER['HTTP_USER_AGENT'])) { $iphone = 1 ; } else { $iphone = 0; } ?
php if ($iphone) { ?
LISTEN
php } else { ?
[audio:https://www.audiomedica.com/podcasting/cardio/090331HORIZONS-AMI-GeorgeDangas.mp3] php } ?…
The 2009 ACC scientific session began with a bang together with the i2 meeting on Saturday March 28th in Orlando, Florida. Peter Goodwin interviewed leading investigators to hear the latest on interventional cardiology, surgery and medical therapy for patients with …
Terje Pedersen
Terje Pedersen, Ulleval University, Oslo
Eugene Braunwald, Harvard University, Boston
Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no benefit in the SEAS (Simvastatin and Ezetimibe In Aortic Stenosis) …
Tony Gershlick
Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing death, MI or urgent revascularisation in the 4,500-patient ISAR-REACT 3 study presented at the …
Felix Zijlstra
Felix Zijlstra, University Medical Center Groningen, The Netherlands
Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits, according to data from the 1000-patient TAPAS study presented at the ACC meeting. Senior investigator Felix …
Barry Massie
Barry Massie, San Francisco VA Medical Center
COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit
The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment and improve acute heart failure symptoms. Barry Massie and Aaron Kugelmass discussed …
Nigel Beckett
Nick Boon
**Nigel Beckett, Imperial College, London
COMMENT: Nick Boon, British Cardiovascular Society, London**
Even very old patients benefit greatly if you treat their hypertension. This is the finding of the randomized HYVET study of 4,000 patients with …
Warren Cantor
Tony Gershlick
REFERENCE: Abstract 2404-3 SCAI-ACCi2 Late-Breaking Clinical Trials II: Acute Myocardial Infarction
**Warren Cantor, University of Toronto
COMMENT: Tony Gershlick, Leicester University**
A new study has shown important gains from adding angioplasty routinely to therapy for all …
Ernst Rietzschel
Jennifer Mieres
REFERENCE: News Briefing, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
**ERNST RIETZSCHEL, University of Ghent, Belgium
COMMENT: JENNIFER MIERES, New York University**
Women who used the contraceptive pill …
Gregg Stone
REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone…
Philip Barter
Gordon Tomaselli
REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
**PHILIP BARTER, Heart Research Institute, Sydney, Australia
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore**…
Ake Hjalmarson
Gordon Tomaselli
REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
**AKE HJALMARSON, Sahlgrenska University, Göteborg
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore**
The lipid …
Uwe Zeymer
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
UWE ZEYMER, Herzzentrum Ludwigshafen, Germany
The glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients …
Gordon Tomaselli
Daniel Jones
REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
**GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson**
A potential new …
Anthony Fung
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
ANTHONY FUNG, University of British Columbia, Vancouver
Brief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as …
Laura Mauri
Raymond Gibbons
REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
**LAURA MAURI, Brigham and Woman’s Hospital, Boston Massachusetts
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester, Minnesota**
The largest study to date looking …
REFERENCE: Abstract: Late Breaking Clinical Trials, Session 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
**LESLEE SHAW, Emory University, Atlanta
COMMENT: DANIEL JONES, AHA President, University of Mississippi, Jackson**
Some patients with stable angina may be best …
Gabriel Steg
Freek Verheugt
REFERENCE: Hotline III, number 709, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
**GABRIEL STEG, Hôpital Bichat, Paris
COMMENT: FREEK VERHEUGT, Radboud University Nijmegen Medical Centre, Nijmegen**
The GRACE registry looking at over 60 …
Stefano Ghio
Cecilia Linde
REFERENCE: Hotline III, 3222 page 315, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
**STEFANO GHIO, San Matteo University Hospital, Italy
COMMENT: CECILIA LINDE, Karolinska University Hospital, Stockholm**
The standard echocardiographic criteria for selecting …
Raul Moreno
REFERENCE: Abstract 3103, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
RAUL MORENO, University Hospital La Paz, Madrid
Results from a large meta analysis suggest that drug eluting stents have a greater benefit when the risk …
Nicolas Amabile
REFERENCE: Abstract 1967, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
NICOLAS AMABILE, University of Marseille School of Medicine
A French study presented at the ESC congress may have found a link between periodontitis and coronary …
Eva Swahn
REFERENCE: HOTLINE II, Monday 8am, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
**EVA SWAHN, University Hospital Linköping, Sweden
COMMENT: ECKART FLECK, Deutsches Herzzentrum, Berlin**
Women who undergo selective invasive treatment for non-ST elevation acute coronary …